{"entity":{"id":"paper-bolla-eortc-22863-nejm-1997","kind":"paper","name":"EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer","aka":[],"tldr":"Adding three years of hormone therapy to radiotherapy for locally advanced prostate cancer improved five-year survival from 62 to 79 percent, establishing long-term androgen deprivation with radiotherapy as the standard for high-risk disease.","summary":"Phase 3 trial of 415 men with locally advanced (T3 to T4 or high-grade T1 to T2) prostate cancer randomised to external beam radiotherapy alone or with goserelin started at the beginning of radiotherapy and continued for three years.\n\nFive-year overall survival was 79 versus 62 percent and disease-free survival 85 versus 48 percent; ten-year follow-up confirmed a persistent survival benefit (58.1 versus 39.8 percent).","asOf":"2026-09-17","links":[{"label":"N Engl J Med 1997","url":"https://doi.org/10.1056/NEJM199707313370502"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/9233866/"}],"tags":[],"related":[],"cancers":["prostate-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":1997,"doi":"10.1056/NEJM199707313370502","pmid":"9233866","authors":"Bolla M, Gonzalez D, Warde P, et al.","paperType":"rct","findings":["Five-year overall survival 79 percent vs 62 percent.","Ten-year overall survival 58.1 percent vs 39.8 percent."],"whatItMeans":"Long-term androgen deprivation (18 to 36 months) with radiotherapy remains the backbone for high-risk localised prostate cancer, to which abiraterone is now added for the highest-risk men.","caveats":["Radiotherapy doses were lower than modern standards.","Optimal duration of hormone therapy was refined by later trials (EORTC 22961, DART 01/05)."],"changedPractice":true,"participants":415},"route":"/key-papers/paper-bolla-eortc-22863-nejm-1997/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}